Table 1 Patient and treatment characteristics
From: Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer
Characteristic | Entire cohort | Surveillance subgroup | sRT subgroup |
|---|---|---|---|
Number of patients | 101 | 65 | 36 |
Age at PET/CT (years), median (range) | 75 (55–92) | 76 (62–92) | 74 (55–80) |
ISUP grade | |||
 1 | 10 (10%) | 10 (15%) | 0 (0%) |
 2 | 38 (38%) | 20 (31%) | 18 (50%) |
 3 | 32 (32%) | 21 (32%) | 11 (31%) |
 4 | 6 (6%) | 3 (5%) | 3 (8%) |
 5 | 12 (12%) | 8 (12%) | 4 (11%) |
 Missing | 3 (3%) | 3 (5%) | 0 (0%) |
Primary tumor classification | |||
 pT2 | 46 (46%) | 27 (42%) | 19 (53%) |
 pT3 | 49 (49%) | 32 (49%) | 17 (47%) |
 Missing | 6 (6%) | 6 (9%) | 0 (0%) |
Primary nodal status | |||
 pN0 | 72 (71%) | 40 (62%) | 32 (89%) |
 pN1 | 10 (10%) | 8 (12%) | 2 (6%) |
 pNx | 14 (14%) | 12 (19%) | 2 (6%) |
 Missing | 5 (5%) | 5 (8%) | 0 (0%) |
Time from diagnosis to recurrence (years), median (range) | 5 (0.5–32) | 7 (0.5–32) | 2 (0.5–16) |
PSA at PET/CT (ng/ml), median (range) | 0.6 (0.4–11.3) | 0.6 (0.4–11.3) | 0.5 (0.4–6.5) |
PSA-DT at PET/CT (mo), median (range) | 6.9 (-221.2–113.8) | 8.2 (-221.2–113.8) | 5.9 (-9.6–99.1) |
PSA velocity at PET/CT (ng/ml/year), median (range) | 0.4 (-838.9–17.5) | 0.3 (-106.4–17.5) | 0.5 (-838.9–9.6) |
Post-PET ADT | 17 (17%) | 0 (0%) | 17 (47%) |
Follow-up time (mo) since PET/CT, median (range) | 39 (12–71) | 42 (12–71) | 36.5 (12–68) |